Open Access
Review

Microorganisms and cardiovascular diseases: importance of gut bacteria

Rashed Noor1,*, Adiba Naz1, Syeda Muntaka Maniha1, Nafisa Tabassum1, Tasmin Tabassum1, Tahsin Tabassum1, Masuma Afrin Taniya1, Muntasir Billah2,3
1
Department of Life Sciences (DLS), School of Environment and Life Sciences (SELS), Independent University, Bangladesh (IUB), 1212 Dhaka, Bangladesh
2
Department of Cardiology, Kolling Institute of Medical Research, Northern Sydney Local Health District, St Leonards, 2065 NSW, Australia
3
Sydney Medical School Northern, University of Sydney, 2006 NSW, Australia
DOI: 10.52586/4921 Volume 26 Issue 5, pp.22-28
Submited: 28 August 2019 Accepted: 25 November 2020 Published: 30 April 2021
(This article belongs to the Special Issue Novel therapeutic approaches to cardiovascular diseases)
*Corresponding Author(s):  
Rashed Noor
E-mail:  
rashednoor@iub.edu.bd
Copyright: © 2021 The author(s). Published by BRI. This is an open access article under the CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).
Abstract

Cardiovascular diseases including myocardial infarctions, myocarditis, strokes, coronary artery disease, chronic granulomatous disease, atherosclerotic cardiovascular disease, etc. can be regarded as the severe health trouble round the globe. The reasons behind the heart related complications have been well chalked our so far. Interestingly, along with the non-­infectious reasons, an array of bacteria, fungi, parasites and viruses is known to cause different types of heart complications. Unfortunately, the role of microorganisms in inducing heart diseases is not that much known by the mass community in the underdeveloped and even in the developing countries over the world. However, among the microorganisms causing heart diseases, the multifaceted bionetwork by the gut microorganisms especially drew the interests of microbiologists. The impairment of cardiac membrane, the metabolic malfunction of heart, and imbalance in the functionality of the immune cells by the alternation in the composition of gut microorganisms are currently not unknown. Present review outlined the onset of heart diseases caused by the gut microflora in a simple way which would be important in public health regard.

Key words

Microorganisms; Cardiovascular diseases; Gut bacteria; Immune cells; Public health; Review

2. Introduction

Cardiovascular disease (CVD) is one of the leading causes of mortality and morbidity worldwide, claiming approximately 17.7 million life per year [1]. Despite making major advancement in the cardiovascular treatment arena, cardiovascular diseases such as heart failure, stroke, myocardial infarction, my ocarditis are still on the rise. Myocardial infarctions, strokes, peripheral vascular disease, heart failure and other CVD’s possess a massive burden on public health.

The presumed cost of alterations in the gut microbiota and the progression of CVD and the cardiometabolic diseases is well known. Though the effects of gut microbiota metabolism of a protein-rich diet have been well studied, however the association of these microorganisms with cardiovascular risk is debatable. The complex ecology of the gut microbiota and its biochemical impacts or the metabolic functionality is a topic of interest for the clinicians, cardiovascular researchers, and food professionals. The present review attempts to demonstrate the link between gut microorganisms and CVD. In addition, we also proposed couple of mechanistic models to explain the gut microorganism’s mode of action in CVD pathology.

3. Important microorganisms causing cardiovascular diseases

Both infectious and non-infectious agents have been implicated to CVD [2]. Blood culture-negative endocarditis (BCNE), accounting for almost 70% of the endocarditis cases [3], has been reported to be diagnosed in the patients previously treated with antibiotics [4]. In addition, presence of slow-growing or intracellular microorganisms like Bartonella quintana, Staphylococcus aureus, Streptococcus equi, and Streptococcus oralis may also cause BCNE [4, 5]. Helicobacter pylori, Mycoplasma pneumonia, Bacillus typhosus and Chlamydia pneumonia, and viral pathogens including fowl adenovirus serotype 4 (FAdV-4), parvovirus B19, Hepatitis C Virus (HCV), Enterovirus (Coxsackie Virus), thecytomegalovirus and herpes simplex viruses have long been known to cause coronary artery disease, myocarditis and pericarditis [6, 7, 8, 9]. Myocarditis caused by Staphylococcus aureus often results into sepsis (bacteria growing in the blood) and may form abscesses in the heart [6]. Among the blood born parasites Borrelia burgdorferi, Ehrlichia and Babesia spp. have been found to be associated with myocarditis [10]. Fungal populations are also known to cause heart diseases. Among them, Aspergillus fumigatus, A. flavus and A. nidulans have been frequently reported [11].

3.1 CVD causing pathogens

Enteric bacteria Staphylococcus aureus, and Mycobacterium as well as fungal pathogens are well documented to cause CVD [12]. Genetic mutations may decrease the intracellular superoxide production by the immune cells like granulocytes (neutrophils and eosinophils). Such response by the granulocytes have been found to trigger the chronic granulomatous disease (CGD), an inherited primary immune deficiency disorder resulting in life-threatening recurrent fungal and bacterial infections of the skin, lungs and bones with associated chronic inflammation or granulomas (Fig. 1). Patients with CGD have been reported to suffer from continual bacterial and fungal infections throughout their life. In CGD, granulocytes, monocytes and macrophages reduce phagocytosis due to the lack of synchronization in the production of reactive oxygen species (ROS) which is required to eliminate the pathogenic microorganisms [11, 13, 14]. Therefore, this is suggestive that CVD inducing microorganisms mainly manifest the opportunistic mode; and CVD is unfortunately caused by the recurrent and/or invasive infections, especially by the catalase-positive bacteria and fungi [11, 15].

. Roles of the inflammatory cytokines; i.e., interleukin (IL) 1B, IL-6, IL-8, and the tumor necrosis factor (TNF) have been shown in this figure. Details are described in the text.

Figure 1: Cardiovascular diseases (CVD) in the forms of chronic granulomatous disease (CGD), coronary artery disease (CAD), cardiometabolic diseases (CMDs), atherosclerotic cardiovascular disease (ACVD) triggered by a vast population of bacteria, fungi, viruses especially the adenovirus serotype 4 (FAdV-4) and Hepatitis C Virus (HCV); by the blood borne parasites. Roles of the inflammatory cytokines; i.e., interleukin (IL) 1B, IL-6, IL-8, and the tumor necrosis factor (TNF) have been shown in this figure. Details are described in the text.

Extensive studies on FAdV-4 have paved the way of understanding the mechanism of virus-induced CVD. It is suggested that, viral infection compromises cardiac integrity and function through the inflammatory cytokines such as interleukin (IL) 1B, IL-6, IL-8, and the tumor necrosis factor (TNF) [16]. In addition, it also hampers the activity of the myocardial enzyme cascade [17]. Moreover, HCV virus may cause myocardial complications through endothelial dysfunction and direct invasion of the arterial wall. Another important pathology of the heart disease is the autoimmune (non-viral) myocarditis, whereby autoantibodies may influence the disease progression [2, 18].

4. The gut microbiome and the protective immunity

The gut microbiota is a complex ecosystem of symbiotic bacteria. It contributes to the mammalian host physiology and metabolism by (i) aiding the processing of the apparently indigestible nutrients, (ii) supplying the necessary metabolites, and (iii) activating the host’s protective immune system to some extent [19, 20]. Macrophages, neutrophils, monocytes, innate lymphoid cells, and bacterial metabolism products like short-chain fatty acids (SCFAs) are known to inhibit the growth of pathogens by producing primary and secondary bile acids, and butyrate [21]. Bacteria and viruses directly produce microbe-associated molecular patterns (MAMPs) on the epithelial cells or on the dendrites [21]. It is followed by the production of interleukin (IL) -22, which in turn promotes the secretion of the antimicrobial peptides (AMPs) and elicit the host innate immunity. Eventually, B cells produce IgA and IgG antibodies that target the pathogenic bacteria in the lumen.

4.1 Gut microbiome and CVD

The gut microorganisms are well known for imparting the protective immunity for the host cells. In contrast, the changes in the gut microbial composition (principally causing the accumulation of the pro-inflammatory molecules) surprisingly plays a substantial physiological role between the host and nutrition. Gut microorganisms also synthesize several metabolites that impair the host metabolic homeostasis and the protective immunological processes, and trigger cardiometabolic diseases (CMD) [20, 22]. CMD has been reported to be caused by the gut microbiome [23, 24].

An array of the gut microbiota including Collinsella, Chryseomonas, Veillonella and Streptococcus has been reported in the coronary artery disease (CAD) patients [25]. Microorganisms like Bacteroidetes, Firmicutes, Actinobacteria, Proteobacteria, and Verrucomicrobia, Fusobacteria, Tenericutes, Spirochaetes, Cyanobacteria, Bifidobacterium, Faecalibacterium, Ruminococcus and Prevotella may also be responsible for the CVD [26, 27]. CAD is linked with gut microbiota alterations in different populations, and gut microbe-derived metabolites may serve as markers for major CVD. A metagenomic study of stool samples from 218 individuals with atherosclerosis (ACVD) and 187 healthy volunteers were compared. Samples from atherosclerotic individuals gut microbiome deviated from the healthy status and was found to contain increased quantity of Enterobacteriaceae and Streptococcus spp. [23].

Besides bacteria, fungal population such as the most common fungal genus Candida, genera of Saccharomyces, Mucor, Fusarium, Malassezia, Penicillium, Aspergillus, Cryptococcus, Malassezia and Cladosporium are also prevalent in the resident gut microbiome [26, 28, 29, 30]. The gastrointestinal (GI) is also dominated by a very small proportion of Archaea like Methanobrevibacter, Methanosphaera, Nitrososphaera, Thermogynomonas, Thermoplasma, Methanomethylophilus alvus [31, 32]. Studies on gut viral population is limited; however, a metagenomic study unraveled the action of a bacteriophage, cross-assembly phage (crAssphage), which is associated with Bacteroides [33].

4.2 How the gut microbiome triggers CVD?

The gut microbiome functions like an endocrine organ, generating the bioactive metabolites that can impact host physiology. Changes in the composition of gut microbiome linked with disease, commonly referred to as dysbiosis, have been reported to be associated with atherosclerosis, hypertension, heart failure, chronic kidney disease, obesity and type 2 diabetes [34]. Alteration/changes within the gut microflora may pose significant impact on the regulation of host biochemical and metabolic design. The knowledge on (i) gut microflora, (ii) associations between the microbiome and the inflammasome, (iii) the innate immune system, (iv) role of bile acids, (v) the gut permeability may aid potential preventive strategy against CVD and coupling microorganisms to the pathogenesis of the autoimmune disease [19, 35, 36, 37, 38, 39].

Indeed, the gut microorganisms are one of the important main factors influencing systemic immune responses and metabolic dysfunctions among the individuals with obesity. It plays a significant role on the onset of the atherosclerosis [40]. Based on the capacity of converting common nutrients to metabolites, the resident microflora within the intestinal tract may act as filters of the diet. The specific microbial-associated metabolites like trimethylamine-N-oxide (TMAO), short-chain fatty acids (SCFAs) and secondary bile acids have been reported to influence CVD development [38]. While the lower gut microbial diversity may be linked with the elevated level of white blood cells and the C-reactive protein (hsCRP) levels; the high loads of gut microorganisms are inversely interrelated to different markers of low-grade inflammation including hsCRP and interleukin (IL) -6 [22, 40].

The impact of gut bacteria on triggering the CVD has been rigorously studied using the advanced technologies till date [22, 41, 42]. One study showed that the products from a protein-rich diet like L-carnitine and phosphatidylcholine was converted to trimethylamine (TMA) by the gut bacteria Escherichia coli, which was further oxidized into TMAO in the liver promoting atherosclerosis and cardiovascular diseases [41]. Elevated level of gut bacterium Collinsella was reported in the carotid artery of symptomatic atherosclerosis patients. However, Lactobacillus rhamnosus GR-1, Bifidobacterium infantis, and Methanomassiliicoccus luminyensis B10 as probiotics were noticed to be effective in treating heart failure in mouse model. It further supports the central role of gut microflora in inducing the CVD [43]. Periodontal pathogens (causing periodontal disease, PD, an inflammatory disease of the oral cavity) such as Porphyromonas gingivalis, Prevotella intermedia, and Fusobacterium nucleatum heightened high-fat diet (HFD) -induced systolic and diastolic arterial pressure in diabetic mice. The lipopolysaccharide (LPS) from P. gingivalis was suggested to be responsible for the inflammation-induced CVD through the elevated oxidative stress (increased ROS) and mitochondrial dysfunction [42]. Another interesting study using mouse model showed the mechanisms by which the microorganisms may control the pathogenic inflammation in the heart and the novel innate immune responses [19]. A generalized model of heart diseases induced by the gut bacteria has been clarified in Fig. 2.

. Details are given in the text.

Figure 2: Generalized model of heart diseases induced by the gut bacteria. Details are given in the text.

4.3 Gut microorganisms, adaptive immunity, autoimmunity, and CVD

The gut bacteria possess several receptors like Lipopolysaccharide (LPS) and pattern recognition receptors (PRR) that stimulate and instruct host immune response [44]. A number of pathways including trimethylamine (TMA)/trimethylamine N-oxide (TMAO) pathway, SCFAs pathway, and primary and secondary bile acid (BAs) pathways are well known interact with the host endocrine hormones including ghrelin, leptin, and glucagon-like peptide 1 (GLP-1) [45]. In perspective of linking adaptive immunity to the CVD, the suppression of immune and inflammatory responses by the glucocorticoid-induced leucine zipper (GILZ) protein has been reported to induce Myocardial infarction (MI) along with a reduced level of Th-17 cells but an elevated level of the anti-inflammatory cytokine IL-10 positive cells [46]. Cytokines, including interferon-γ, transforming growth factor-β1, interleukin-1β are also involved in the process [47].

From the evidences of a range of clinical research as well as through a vast biotechnological application, a large number of microorganisms have been identified to provide both beneficial and harmful impacts to human health. While the advantageous effects are generated from the symbiotic relationship between the normal flora (microorganisms residing within the host as the first line of immune defense) and the host, the destruction of host immunity or the metabolic or genetic alternations among the microbiome may turn those into the opportunistic pathogens, causing infections including the systemic rheumatic diseases [48]. Interestingly, another recent study has shown that alteration in gut microbiome can trigger the CVD and autoimmune disease [49]. An important gut bacterium, Roseburia intestinalis, has been reported to trigger inflammation in patients with the antiphospholipid syndrome (APS) [50]. Surprisingly, their gut immune cells produce antibodies to kill their own cells [50, 51]. Probiotic treatment with Lactobacilli reversed the condition by restoring the composition of the gut microbiome [52]. Certain advanced microbiological methods and molecular biological techniques have been found to be very useful in the detection of microorganisms associated with heart diseases. Advanced molecular methods like the polymerase chain reaction, 16S rRNA sequencing, and next-generation sequencing have been shown to be effective for the direct detection of microbial pathogens in CVD including infective endocarditis [53, 54]. Such molecular tools are an excellent alternative to the culture-based methods, particularly in detecting the viable but non-culturable pathogenic microorganisms [53].

5. Conclusions

In our opinion, the proposed models presented in the current review would highlight the mechanism of bacteria-induced CVD. An idea on the alterations in the gut microbiota along with their metabolic strategies would be of interest both for the biochemists and the food microbiologists. Thus, the objectives of this very review are expected to meet the current knowledge demand for the linkage between the complex microbial ecology and the cardiovascular diseases. Further deciphering the molecular mechanisms of microbial attach of heart would be of great interest. Another important point to ponder is that the cardiovascular disease is progressively more imperative basis of clinical fatality in Bangladesh. The cases of coronary artery disease, hypertension, etc. are of current epidemic importance. Different environmental and dietary risk factors are commonly analyzed for heart diseases; however, the involvement of microorganisms triggering heart related complications are ignored. Therefore, not only in the general global aspect, rather, for the welfare of the mass public health, the knowledge from the current review would be useful in local perspective.

6. Author contributions

RN conceived and designed the research project and interpreted the data. RN, AN, SMM and MB contributed writing and editing the manuscript. AN, SMM, MB, NT, TasT, TahT and MAT conducted the literature survey and gathered the required information to write the review. MB, NT, TasT, TahT and MAT also helped in formatting the manuscript. All authors read and approved the final manuscript.

7. Ethics approval and consent to participate

Not applicable.

8. Acknowledgment

Authors acknowledge the groups whose literatures have been cited to write this review.

9. Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

10. Conflict of interest

The authors report no relationships that could be construed as a conflict of interest.

Abbreviations

ACVD, atherosclerotic cardiovascular disease; AMPs, antimicrobial peptides; APS, antiphospholipid syndrome; BCNE, blood culture-negative endocarditis; CAD, coronary artery disease; CGD, chronic granulomatous disease; CMDs, cardiometabolic diseases; CVD, cardiovascular diseases; FAdV-4, fowl adenovirus serotype 4; GILZ, glucocorticoid-induced leucine zipper; GLP-1, glucagon-like peptide 1; HCV, Hepatitis C virus; HFD, heightened high-fat diet; HPS, hydropericardium syndrome; hsCRP, C-reactive protein; IL, interleukin; MAMPs, microbe-associate molecular patterns; LPS, lipopolysaccharide; PRR, pattern recognition receptors; SCAD, stable coronary artery disease; SCFAs, short-chain fatty acids; TMA, trimethylamine; TMAO, trimethylamine N-oxide; UA, unstable angina.

References
  • [1] Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018; 137: e67–e492.
  • [2] Muller AM, Fischer A, Katus HA, Kaya Z. Mouse models of autoimmune diseases - autoimmune myocarditis. Current Pharmaceutical Design. 2015; 21: 2498–2512.
  • [3] Fournier P, Gouriet F, Casalta J, Lepidi H, Chaudet H, Thuny F, et al. Blood culture-negative endocarditis. Medicine. 2017; 96: e8392.
  • [4] Boudebouch N, Sarih M, Chakib A, Fadili S, Boumzebra D, Zouizra Z, et al. Blood culture-negative endocarditis, morocco. Emerging Infectious Diseases. 2017; 23: 1908–1909.
  • [5] Brouqui P, Raoult D. Endocarditis due to rare and fastidious bacteria. Clinical Microbiology Reviews. 2001; 14: 177–207.
  • [6] Mavrouli MD, Spanakis N, Levidiotou S, Politi C, Alexiou S, Tseliou P, et al. Serologic prevalence of coxsackievirus group B in Greece. Viral Immunology. 2007; 20: 11–18.
  • [7] Hopkins KA, Abdou MH, Hadi MA. Coxsackie B2 virus infection causing multiorgan failure and cardiogenic shock in a 42-year-old man. Texas Heart Institute Journal. 2019; 46: 32–35.
  • [8] Babiker A, Jeudy J, Kligerman S, Khambaty M, Shah A, Bagchi S. Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: a Review. Journal of Clinical and Translational Hepatology. 2017; 5: 1–20.
  • [9] Institute of Medicine (US) Forum on Microbial Threats. The infectious etiology of chronic diseases: defining the relationship, enhancing the research, and mitigating the effects: workshop summary. Washington, DC: The National Academies Press. 2004.
  • [10] Connolly SE, Benach JL. The versatile roles of antibodies in Borrelia infections. Nature Reviews Microbiology. 2005; 3: 411–420.
  • [11] Mortaz E, Sarhifynia S, Marjani M, Moniri A, Mansouri D, Mehrian P, et al. An adult autosomal recessive chronic granulomatous disease patient with pulmonary Aspergillus terreus infection. BMC Infectious Diseases. 2018; 18: 552.
  • [12] Buvelot H, Posfay-Barbe KM, Linder P, Schrenzel J, Krause K. Staphylococcus aureus, phagocyte NADPH oxidase and chronic granulomatous disease. FEMS Microbiology Reviews. 2017; 41: 139–157.
  • [13] Beauté J, Obenga G, Le Mignot L, Mahlaoui N, Bougnoux M, Mouy R, et al. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France. The Pediatric Infectious Disease Journal. 2011; 30: 57–62.
  • [14] Marciano BE, Spalding C, Fitzgerald A, Mann D, Brown T, Osgood S, et al. Common severe infections in chronic granulomatous disease. Clinical Infectious Diseases. 2015; 60: 1176–1183.
  • [15] van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, et al. Chronic granulomatous disease: the European experience. PLoS ONE. 2009; 4: e5234.
  • [16] Liu H, Chen X, Hu X, Niu H, Tian R, Wang H, et al. Alterations in the gut microbiome and metabolism with coronary artery disease severity. Microbiome. 2019; 7: 68.
  • [17] Niu Y, Sun Q, Liu X, Liu S. Mechanism of fowl adenovirus serotype 4-induced heart damage and formation of pericardial effusion. Poultry Science. 2019; 98: 1134–1145.
  • [18] Li HS, Ligons DL, Rose NR. Genetic complexity of autoimmune myocarditis. Autoimmunity Reviews. 2008; 7: 168–173.
  • [19] Barin JG, Talor MV, Diny NL, Ong S, Schaub JA, Gebremariam E, et al. Regulation of autoimmune myocarditis by host responses to the microbiome. Experimental and Molecular Pathology. 2017; 103: 141–152.
  • [20] Brial F, Le Lay A, Dumas M, Gauguier D. Implication of gut microbiota metabolites in cardiovascular and metabolic diseases. Cellular and Molecular Life Sciences. 2018; 75: 3977–3990.
  • [21] Pickard JM, Zeng MY, Caruso R, Núñez G. Gut microbiota: role in pathogen colonization, immune responses, and inflammatory disease. Immunological Reviews. 2017; 279: 70–89.
  • [22] Schiattarella GG, Sannino A, Esposito G, Perrino C. Diagnostics and therapeutic implications of gut microbiota alterations in cardiometabolic diseases. Trends in Cardiovascular Medicine. 2019; 29: 141–147.
  • [23] Jie Z, Xia H, Zhong S, Feng Q, Li S, Liang S, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nature Communications. 2017; 8: 845.
  • [24] Wang J, Jia H. Metagenome-wide association studies: fine-mining the microbiome. Nature Reviews Microbiology. 2016; 14: 508–522.
  • [25] Koren O, Spor A, Felin J, Fak F, Stombaugh J, Tremaroli V, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proceedings of the National Academy of Sciences. 2011; 108: 4592–4598.
  • [26] Hillman ET, Lu H, Yao T, Nakatsu CH. Microbial ecology along the gastrointestinal tract. Microbes and Environments. 2017; 32: 300–313.
  • [27] Huse SM, Dethlefsen L, Huber JA, Mark Welch D, Welch DM, Relman DA, et al. Exploring microbial diversity and taxonomy using SSU rRNA hypervariable tag sequencing. PLoS Genetics. 2008; 4: e1000255.
  • [28] Gouba N, Drancourt M. Digestive tract mycobiota: a source of infection. Medecine Et Maladies Infectieuses. 2015; 45: 9–16.
  • [29] Cui L, Morris A, Ghedin E. The human mycobiome in health and disease. Genome Medicine. 2013; 5: 63.
  • [30] Hoffmann C, Dollive S, Grunberg S, Chen J, Li H, Wu GD, et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS ONE. 2013; 8: e66019.
  • [31] Dridi B, Raoult D, Drancourt M. Archaea as emerging organisms in complex human microbiomes. Anaerobe. 2011; 17: 56–63.
  • [32] Gaci N, Borrel G, Tottey W, O’Toole PW, Brugère J. Archaea and the human gut: new beginning of an old story. World Journal of Gastroenterology. 2014; 20: 16062.
  • [33] Dutilh BE, Cassman N, McNair K, Sanchez SE, Silva GGZ, Boling L, et al. A highly abundant bacteriophage discovered in the unknown sequences of human faecal metagenomes. Nature Communications. 2014; 5: 4498.
  • [34] Yamashiro K, Tanaka R, Urabe T, Ueno Y, Yamashiro Y, Nomoto K, et al. Gut dysbiosis is associated with metabolism and systemic inflammation in patients with ischemic stroke. PLoS ONE. 2017; 12: e0171521.
  • [35] Tripathi A, Xu ZZ, Xue J, Poulsen O, Gonzalez A, Humphrey G, et al. Intermittent hypoxia and hypercapnia reproducibly change the gut microbiome and metabolome across rodent model systems. MSystems. 2019; 4: e00058–19.
  • [36] Xu M, Liu PP, Li H. Innate immune signaling and its role in metabolic and cardiovascular diseases. Physiological Reviews. 2019; 99: 893–948.
  • [37] Adamczyk-Sowa M, Medrek A, Madej P, Michlicka W, Dobrakowski P. Does the gut microbiota influence immunity and inflammation in multiple sclerosis pathophysiology? Journal of Immunology Research. 2017; 2017: 7904821.
  • [38] Tang WHW, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circulation Research. 2017; 120: 1183–1196.
  • [39] Levy M, Thaiss C, Zeevi D, Dohnalová L, Zilberman-Schapira G, Mahdi J, et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell. 2015; 163: 1428–1443.
  • [40] van den Munckhof ICL, Kurilshikov A, Ter Horst R, Riksen NP, Joosten LAB, Zhernakova A, et al. Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease: a systematic review of human studies. Obesity Reviews. 2018; 19: 1719–1734.
  • [41] Serino M, Blasco-Baque V, Nicolas S, Burcelin R. Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences. Current Cardiology Reports. 2014; 16: 540.
  • [42] Bullon P, Cordero MD, Quiles JL, Morillo JM, del Carmen Ramirez-Tortosa M, Battino M. Mitochondrial dysfunction promoted by Porphyromonas gingivalis lipopolysaccharide as a possible link between cardiovascular disease and periodontitis. Free Radical Biology & Medicine. 2011; 50: 1336–1343.
  • [43] Gan XT, Ettinger G, Huang CX, Burton JP, Haist JV, Rajapurohitam V, et al. Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circulation Heart Failure. 2014; 7: 491–499.
  • [44] Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009; 58: 1091–1103.
  • [45] De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014; 156: 84–96.
  • [46] Baban B, Yin L, Qin X, Liu JY, Shi X, Mozaffari MS. The role of GILZ in modulation of adaptive immunity in a murine model of myocardial infarction. Experimental and Molecular Pathology. 2017; 102: 408–414.
  • [47] McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Progress in Lipid Research. 2011; 50: 331–347.
  • [48] Chanda W, Joseph TP, Guo X, Wang W, Liu M, Vuai MS, et al. Effectiveness of omega-3 polyunsaturated fatty acids against microbial pathogens. Journal of Zhejiang University-Science B. 2018; 19: 253–262.
  • [49] Kasselman LJ, Vernice NA, DeLeon J, Reiss AB. The gut microbiome and elevated cardiovascular risk in obesity and autoimmunity. Atherosclerosis. 2018; 271: 203–213.
  • [50] Butt AA, Yan P, Shuaib A, Abou-Samra A, Shaikh OS, Freiberg MS. Direct-acting antiviral therapy for HCV infection is associated with a reduced risk of cardiovascular disease events. Gastroenterology. 2019; 156: 987–996.e8.
  • [51] Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. The New England Journal of Medicine. 2016; 375: 2369–2379.
  • [52] Ruff WE, Dehner C, Kim WJ, Pagovich O, Aguiar CL, Yu AT, et al. Pathogenic autoreactive T and B cells cross-react with mimotopes expressed by a common human gut commensal to trigger autoimmunity. Cell Host & Microbe. 2019; 26: 100–113.e8.
  • [53] Cheng J, Hu H, Fang W, Shi D, Liang C, Sun Y, et al. Detection of pathogens from resected heart valves of patients with infective endocarditis by next-generation sequencing. International Journal of Infectious Diseases. 2019; 83: 148–153.
  • [54] Peeters B, Herijgers P, Beuselinck K, Verhaegen J, Peetermans WE, Herregods MC, et al. Added diagnostic value and impact on antimicrobial therapy of 16S rRNA PCR and amplicon sequencing on resected heart valves in infective endocarditis: a prospective cohort study. Clinical Microbiology and Infection. 2017; 23: 888.e1–888.e5.
Share and Cite
Rashed Noor, Adiba Naz, Syeda Muntaka Maniha, Nafisa Tabassum, Tasmin Tabassum, Tahsin Tabassum, Masuma Afrin Taniya, Muntasir Billah. Microorganisms and cardiovascular diseases: importance of gut bacteria. Frontiers in Bioscience-Landmark. 2021. 26(5); 22-28.